Thomas Gundelund Rasmussen

Thomas Gundelund Rasmussen is an accomplished executive with extensive experience in business development and operations within the biotechnology and pharmaceutical sectors. Currently serving as Chief Business Officer and Chief Operating Officer at Kynexis, Thomas has played a crucial role in launching the transatlantic company and advancing it to the initiation of first-in-human trials in under twelve months. As an Operating Partner at Forbion and Entrepreneur for various immunology biotechs, Thomas focuses on building impactful companies addressing significant patient needs. Thomas founded Freya Biosciences to develop disease-modifying therapies for infertility, and previously held leadership positions at VectorY, Kaleido Biosciences, and Chr. Hansen, where contributions included driving major joint ventures and developing innovative microbial solutions. Thomas's academic credentials include degrees from prestigious institutions such as Harvard Law School, Stanford University, and DTU, alongside a year of intensive Chinese language study.